REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. National Cancer Institute-Surveillance, epidemiology, and end results program. Cancer stat facts: prostate cancer. Available from: https://seer.cancer.gov/statfacts/html/prost.html. [Last accessed on 18 Feb 2025].
3. Piombino C, Oltrecolli M, Tonni E et al. De novo metastatic prostate cancer: are we moving toward a personalized treatment? Cancers. 2023;15:4945.
4. Rocco B, Sighinolfi MC, Coelho RF, Patel V. Re: trends in incidence of metastatic prostate cancer in the US. Eur Urol. 2022;82:332-3.
5. He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:198.
6. Riaz IB, Naqvi SAA, He H, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9:635-45.
7. Tucci M, Bertaglia V, Vignani F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563-73.
8. Singer EA, Srinivasan R. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol. 2012;30:S15-9.
9. Labriola MK, Atiq S, Hirshman N, Bitting RL. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis. 2021;24:301-9.
10. Scher HI, Morris MJ, Stadler WM et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-18.
11. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479-99.
12. Pond GR, Sonpavde G, De Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3-6.
13. Mosillo C, Calandrella ML, Caserta C, et al. Targeted approaches in metastatic castration-resistant prostate cancer: which data? Cancers. 2022;14:4189.
14. Halabi S, Kelly WK, Ma H et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652-9.
15. Fizazi K, Massard C, Smith M et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42-50.
16. Brighi N, Conteduca V, Lolli C, et al. Corrigendum to “The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives” [Crit. Rev. Oncol. Hematol. 157 (January) (2021) 103199]. Crit Rev Oncol Hematol. 2021;164:103401.
17. Obinata D, Takayama K, Inoue S, Takahashi S. Exploring androgen receptor signaling pathway in prostate cancer: a path to new discoveries. Int J Urol. 2024;Epub ahead of print.
18. Harris AE, Metzler VM, Lothion-Roy J, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol. 2022;13:1006101.
19. Schaeffer EM, Lurie RH, Adra N et al. NCCN guidelines® insights: prostate cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22:140-50.
20. Maitland NJ. Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced? Cancers. 2021;13:327.
21. Ehsani M, David FO, Baniahmad A. Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers. 2021;13:1534.
22. Le TK, Duong QH, Baylot V, et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers. 2023;15:5047.
23. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701-11.
24. Crowley F, Sterpi M, Buckley C, Margetich L, Handa S, Dovey Z. A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer. Res Rep Urol. 2021;13:457-72.
25. Arora VK, Schenkein E, Murali R et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309-22.
26. Narayanan R. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. Asian J Urol. 2020;7:271-83.
27. Li H, Wang Z, Tang K, et al. Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis. Eur Urol Focus. 2018;4:529-39.
28. Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol. 2019;37:1120-9.
29. Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE. Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer. 2020;18:1-10.
30. National Cancer Institute. Abiraterone acetate, niclosamide, and prednisone in treating patients with castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-00779. [Last accessed on 18 Feb 2025].
31. National Cancer Institute. Niclosamide and enzalutamide in treating patients with castration-resistant, metastatic prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2015-01246. [Last accessed on 18 Feb 2025].
32. Yehya A, Ghamlouche F, Zahwe A, et al. Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resist. 2022;5:667-90.
33. Samaržija I. Post-translational modifications that drive prostate cancer progression. Biomolecules. 2021;11:247.
34. Lumahan LEV, Arif M, Whitener AE, Yi P. Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications. Cells. 2024;13:191.
35. McAllister MJ, McCall P, Dickson A et al. Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:596-606.
36. Fu M, Rao M, Wang C et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003;23:8563-75.
37. Hwang JW, Cho Y, Bae G-U, Kim S-N, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53:788-808.
38. Li W, Wang Z. Ubiquitination process mediates prostate cancer development and metastasis through multiple mechanisms. Cell Biochem Biophys. 2024;82:77-90.
39. Long MD, Jacobi JJ, Singh PK et al. Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Rep. 2021;37:110109.
40. Armstrong CM, Gao AC. Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer. Am J Clin Exp Urol. 2021;9:292-300.
42. Meng L, Yang Y, Mortazavi A, Zhang J. Emerging immunotherapy approaches for treating prostate cancer. Int J Mol Sci. 2023;24:14347.
43. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
44. Jiao S, Subudhi SK, Aparicio A, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179:1177-90.e13.
45. Lin M, Sun X, Lv L. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Mol Ther Oncolytics. 2023;29:91-106.
46. Rehman LU, Nisar MH, Fatima W, et al. Immunotherapy for prostate cancer: a current systematic review and patient centric perspectives. J Clin Med. 2023;12:1446.
47. Farhangnia P, Ghomi SM, Akbarpour M, Delbandi AA. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023;14:1155778.
48. Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11:475-86.
49. Hirz T, Mei S, Sarkar H et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.
50. Bian X, Wang W, Abudurexiti M et al. Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci. 2024;11:2305724.
51. Feriz AM, Khosrojerdi A, Lotfollahi M et al. Single-cell RNA sequencing uncovers heterogeneous transcriptional signatures in tumor-infiltrated dendritic cells in prostate cancer. Heliyon. 2023;9:e15694.
52. Hawley JE, Obradovic AZ, Dallos MC, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell. 2023;41:1972-88.e5.
53. Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85:108-16.
54. Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK. Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018;36:349-60.
55. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9:652-64.
56. Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5:1411-20.
57. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
58. Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807-13.
59. Antonarakis E, Piulats J, Gross-goupil M, et al. 611P pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Ann Oncol. 2021;32:S651-2.
60. Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395-405.
61. Zhang W, Van Gent DC, Incrocci L, Van Weerden WM, Nonnekens J. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis. 2020;23:24-37.
62. Rodrigues DN, Rescigno P, Liu D et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128:4441-53.
63. Grypari I-M, Tzelepi V, Gyftopoulos K. DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology. Int J Mol Sci. 2023;24:11418.
64. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753-8.
65. Abida W, Cheng ML, Armenia J et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA oncol. 2019;5:471-8.
66. Tucker MD, Zhu J, Marin D et al. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med. 2019;8:4644-55.
67. Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell. 2020;38:489-99.e3.
68. Cha HR, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80:1615-23.
69. Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144-53.
70. Graff JN, Liang LW, Kim J, Stenzl A. KEYNOTE-641: a phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 2021;17:3017-26.
71. Antonarakis ES, Park SH, Goh JC, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41:3839-50.
72. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-102.
73. Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers. 2023;15:2912.
74. Petrylak D, Li B, Schloss C, Fizazi K. 891TiP - KEYNOTE-921: phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2019;30:v351.
75. Petrylak DP, Ratta R, Gafanov R, et al. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021;17:3291-9.
76. Drake C, Saad F, Clark W, et al. 690TiP a phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX). Ann Oncol. 2020;31:S546.
77. Larvol Clin Cancer Trial Results. A study of chemoimmunotherapy for the treatment of men with neuroendocrine or aggressive variant metastatic prostate cancer. Available from: https://clin.larvol.com/trial-detail/NCT04709276. [Last accessed on 18 Feb 2025].
78. ClinicalTrials.gov. Pembrolizumab, carboplatin and cabazitaxel in aggressive metastatic castration resistant prostate cancer (PEAPOD_FOS) (PEAPOD_FOS). Available from: https://clinicaltrials.gov/study/NCT05563558. [Last accessed on 19 Feb 2025].
79. National Cancer Institute. ZEN-3694, enzalutamide, and pembrolizumab for the treatment of metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-04495. [Last accessed on 18 Feb 2025].
80. National Cancer Institute. Pembrolizumab and lenvatinib in advanced/metastatic neuroendocrine prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-06868. [Last accessed on 18 Feb 2025].
81. ClinicalTrials.gov. Study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY). Available from: https://clinicaltrials.gov/study/NCT05502315. [Last accessed on 19 Feb 2025].
82. National Cancer Institute. Vidutolimod (CMP-001) in combination with nivolumab for the treatment of metastatic castration resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-05290. [Last accessed on 18 Feb 2025].
83. National Cancer Institute. DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-02916. [Last accessed on 18 Feb 2025].
84. National Cancer Institute. Study to evaluate CCS1477 in advanced tumours. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-09704. [Last accessed on 18 Feb 2025].
85. National Cancer Institute. Cabozantinib and atezolizumab for the treatment of metastatic castration-resistant prostate cancer, the AtezoCab trial. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-13110. [Last accessed on 18 Feb 2025].
86. National Cancer Institute. Study of XL092 in combination with immuno-oncology agents in subjects with solid tumors. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-05617. [Last accessed on 18 Feb 2025].
87. National Cancer Institute. The evaluation of PC14586 in patients with advanced solid tumors harboring a TP53 Y220C mutation (PYNNACLE). Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04585750. [Last accessed on 18 Feb 2025].
88. National Cancer Institute. Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-01266&r=1. [Last accessed on 18 Feb 2025].
89. National Cancer Institute. Study of NGM831 as monotherapy and in combination with pembrolizumab or pembrolizumab and NGM438 in advanced or metastatic solid tumors. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-01100&r=1. [Last accessed on 18 Feb 2025].
90. Lohiya V, Aragon-Ching JB, Sonpavde G. Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2016;10:57-66.
91. de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54.
92. Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 2017;19:13.
93. Odero-marah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-mesenchymal transition (EMT) and prostate cancer. In: Schatten H, Editor. Cell & molecular biology of prostate cancer. Cham: Springer International Publishing; 2018. pp. 101-10.
94. Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745-56.
95. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-23.
96. Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023;24:11626.
97. Gillessen S, Choudhury A, Saad F, et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333/PEACE-3. Ann Oncol. 2024;35:S1254.
98. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-103.
99. Hofman MS, Emmett L, Sandhu S, et al; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804.
100. Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book. 2022;42:1-17.
101. Kulkarni H, Singh A, Baum R. Response assessment to treatment with Lu-177 labeled PSMA inhibitor in patients with metastatic castration-resistant prostate cancer: differential response of bone versus lymph node lesions. Available from: https://www.researchgate.net/publication/304139671_Response_assessment_to_treatment_with_Lu-177_labeled_PSMA_inhibitor_in_patients_with_metastatic_castration-resistant_prostate_cancer_differential_response_of_bone_versus_lymph_node_lesions. [Last accessed on 18 Feb 2025].
102. Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45:935-42.
103. Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 2021;62:989-95.
104. Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.
105. Makvandi M, Dupis E, Engle JW, et al. Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018;13:189-203.
106. Sayar E, Patel RA, Coleman IM et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI insight. 2023;8:e162907.
107. Arbuznikova D, Eder M, Grosu A-L et al. Towards improving the efficacy of psma-targeting radionuclide therapy for late-stage prostate cancer-combination strategies. Curr Oncol Rep. 2023;25:1363-74.
108. Ruigrok EA, Verkaik NS, de Blois E et al. Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment. Int J Mol Sci. 2022;23:8037.
109. Mass AC, Runge R, Wetzig K, Huebinger L, Brogsitter C, Kotzerke J. Enhancing effects of olaparib by alpha-and beta-emitting radionuclides, X-rays, and ultraviolet a light in combination with ortho-iodohoechst in a prostate cancer cell model. Pharmaceuticals. 2024;17:1450.
110. Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773-91.
111. Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021;14:51.
112. Tsujino T, Takai T, Hinohara K et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14:252.
113. Miao C, Tsujino T, Takai T et al. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv. 2022;8:eabl9794.
114. Giudice E, Gentile M, Salutari V, et al. PARP inhibitors resistance: mechanisms and perspectives. Cancers. 2022;14:1420.
115. Taavitsainen S, Engedal N, Cao S et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12:5307.
116. Horning AM, Wang Y, Lin C-K et al. Single-Cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response. Cancer Res. 2018;78:853-64.
117. Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15.
118. National Cancer Institute. Testing the safety and effectiveness of radiation-based treatment (lutetium Lu 177 dotatate) for metastatic prostate cancer that has neuroendocrine cells. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-05173. [Last accessed on 18 Feb 2025].
119. National Cancer Institute. A study of peluntamig (PT217) in patients with neuroendocrine carcinomas expressing DLL3 (the SKYBRIDGE study). Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-04193. [Last accessed on 18 Feb 2025].
120. ClinicalTrials.gov. A study in participants with advanced cancers associated with expression of DLL3 (MK-6070-001/HPN328-4001). Available from: https://clinicaltrials.gov/study/NCT04471727. [Last accessed on 19 Feb 2025].
121. National Cancer Institute. A Study of tinengotinib (TT-00420) in combination with standard treatments in people with prostate cancer, TIP trial. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-05117. [Last accessed on 18 Feb 2025].
122. CTV. Study of TGF-β receptor inhibitor galunisertib (LY2157299) and enzalutamide in metastatic castration-resistant prostate cancer. Available from: https://ctv.veeva.com/study/study-of-tgf-b-receptor-inhibitor-galunisertib-ly2157299-and-enzalutamide-in-metastatic-castration?comeFrom=study-search. [Last accessed on 18 Feb 2025].
123. Jamaspishvili T, Berman DM, Ross AE et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222-34.
124. Sweeney C, Bracarda S, Sternberg CN et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131-42.
125. ClinicalTrials.gov. Study of ipatasertib or apitolisib with abiraterone acetate versus abiraterone acetate in participants with castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Available from: https://www.clinicaltrials.gov/study/NCT01485861. [Last accessed on 18 Feb 2025].
126. National Cancer Institute. Gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-00175. [Last accessed on 18 Feb 2025].
127. National Cancer Institute. Study of capivasertib + docetaxel vs placebo + docetaxel as treatment for metastatic castration resistant prostate cancer (mCRPC). Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04699. [Last accessed on 18 Feb 2025].
128. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014;33:595-606.
129. Araujo JC, Trudel GC, Saad F et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307-16.
130. Schneider JA, Logan SK. Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol Cell Endocrinol. 2018;462:3-8.
131. WCG CenterWatch. Study of docetaxel combined with cirmtuzumab in metastatic castration resistant prostate cancer. Available from: https://www.centerwatch.com/clinical-trials/listings/NCT05156905/study-of-docetaxel-combined-with-cirmtuzumab-in-metastatic-castration-resistant-prostate-cancer?id=305&slug=abdominal-cancer. [Last accessed on 18 Feb 2025].
132. ClinicalTrials.gov. Abemaciclib with or without atezolizumab for mCRPC. Available from: https://clinicaltrials.gov/study/NCT04751929. [Last accessed on 19 Feb 2025].
134. Weichert W, Röske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604-10.
135. ClinicalTrials.gov. Talazoparib in combination with belinostat for metastatic breast cancer, metastatic castration resistant prostate cancer, and metastatic ovarian cancer. Available from: https://clinicaltrials.gov/study/NCT04703920. [Last accessed on 19 Feb 2025].
136. Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer. 2015;13:22-31.
137. Luke JJ, Sharma M, Chandana SR, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a phase 1 expansion (exp) cohort. JCO. 2023;41:155.
138. National Cancer Institute. XmAb®20717 (vudalimab) alone or in combination with chemotherapy or targeted therapy in patients with metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-09181. [Last accessed on 18 Feb 2025].
139. Carebox. Autologous gamma delta T cells to target prostate stem cell antigen in mCRPC. Available from: https://connect.careboxhealth.com/en-US/trial/listing/448495. [Last accessed on 18 Feb 2025].
140. Carebox. Clinical study of safety and efficacy of enhanced PSMA CAR- T in refractory CRPC. Available from: https://connect.careboxhealth.com/en-US/trial/listing/454616. [Last accessed on 18 Feb 2025].
141. Carebox. LuCarbo - a study of 177Lu-PSMA-617 plus carboplatin in metastatic castrate-resistant prostate cancer. Available from: https://connect.careboxhealth.com/en-US/trial/listing/467581. [Last accessed on 18 Feb 2025].
142. CTV. pTVG-HP DNA vaccine with or without pTVG-AR DNA vaccine and pembrolizumab in patients with castration-resistant, metastatic prostate cancer. Available from: https://ctv.veeva.com/study/ptvg-hp-dna-vaccine-with-or-without-ptvg-ar-dna-vaccine-and-pembrolizumab-in-patients-with-castratio. [Last accessed on 18 Feb 2025].
143. Center for oncology research & education. ARX517 in subjects with metastatic castration-resistant prostate cancer. Available from: https://www.georgiacancerinfo.org/clinical-trials/detail/5407. [Last accessed on 18 Feb 2025].
144. Lampe H, Tam L, Hansen AR. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future. Front Pharmacol. 2024;15:1399802.
145. Simão DC, Zarrabi KK, Mendes JL, et al. Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer. Cancers. 2023;15:1412.
146. Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126:3192-201.
147. Piron B, Bastien M, Antier C, et al. Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen. Haematologica. 2024;109:357-61.
148. Heitmann JS, Pfluegler M, Jung G, Salih HR. Bispecific antibodies in prostate cancer therapy: current status and perspectives. Cancers. 2021;13:549.
149. Miyahira AK, Soule HR. The 27th annual prostate cancer foundation scientific retreat report. Prostate. 2021;81:1107-24.
150. Falchook GS, McKean M, Kelly WK et al. Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:16.
151. Wire B. Janux announces doses selected for phase 1b expansion trials supported by encouraging efficacy and safety profile observed in phase 1a dose escalation for JANX007 in mCRPC. Available from: https://www.businesswire.com/news/home/20241202674893/en/Janux-Announces-Doses-Selected-for-Phase-1b-Expansion-Trials-Supported-by-Encouraging-Efficacy-and-Safety-Profile-Observed-in-Phase-1a-Dose-Escalation-for-JANX007-in-mCRPC. [Last accessed on 18 Feb 2025].
152. ClinicalTrials.gov. A study of lorigerlimab with docetaxel or docetaxel alone in participants with metastatic castration-resistant prostate cancer. Available from: https://clinicaltrials.gov/study/NCT05848011. [Last accessed on 19 Feb 2025].
153. National Cancer Institute. A study of JNJ-78278343, a T-cell-redirecting agent targeting human kallikrein 2 (KLK2), for advanced prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-01523. [Last accessed on 18 Feb 2025].
154. National Cancer Institute. Study evaluating zenocutuzumab in patients with or without molecularly defined cancers. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-01619. [Last accessed on 18 Feb 2025].
155. National Cancer Institute. Trial of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer (mCRPC) resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04331. [Last accessed on 18 Feb 2025].
156. ClinicalTrials.gov. Vudalimab (XmAb20717) in combination with standard of care treatment in patients with metastatic castration sensitive prostate cancer. Available from: https://clinicaltrials.gov/study/NCT05733351. [Last accessed on 19 Feb 2025].
158. Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14.
159. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3-9.
160. Ramos CA, Rouce R, Robertson CS, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin’s lymphomas. Mol Ther. 2018;26:2727-37.
161. Schepisi G, Cursano MC, Casadei C, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer. 2019;7:258.
162. Dorff TB, Blanchard MS, Adkins LN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30:1636-44.
163. Tschernia NP, Norberg SM, Gulley JL. CAR T cells reach clinical milestone in prostate cancer. Nat Med. 2022;28:635-6.
164. Narayan V, Barber-Rotenberg JS, Jung IY, et al. Prostate Cancer Cellular Therapy Program Investigators. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724-34.
165. Narayan V, Barber-Rotenberg JS, Jung IY, et al; Prostate Cancer Cellular Therapy Program Investigators. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724-34.
166. Wolf P, Alzubi J, Gratzke C, Cathomen T. The potential of CAR T cell therapy for prostate cancer. Nat Rev Urol. 2021;18:556-71.
167. Santomasso BD, Nastoupil LJ, Adkins S et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978-92.
168. Perera MP, Thomas PB, Risbridger GP et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers. 2022;14:503.
169. Lee DW, Santomasso BD, Locke FL et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-38.
170. Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3:100543.
171. Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28:2320-39.
172. National Cancer Institute. PSCA-targeting CAR-T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02186. [Last accessed on 18 Feb 2025].
173. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254-62.
174. Mjaess G, Aoun F, Rassy E, Diamand R, Albisinni S, Roumeguère T. Antibody-drug conjugates in prostate cancer: where are we? Clin Genitourin Cancer. 2023;21:171-4.
175. UCSF Clinical Trials. FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer. Available from: https://clinicaltrials.ucsf.edu/trial/NCT05011188. [Last accessed on 18 Feb 2025].
176. CTV. Disitamab vedotin in the treatment with HER2- expression, subjects with locally advanced or metastatic castration-resistant prostate cancer. Available from: https://ctv.veeva.com/study/dv-with-her2-expression-gene-amplification-or-mutation-metastatic-castration-resistant-prostate-can. [Last accessed on 18 Feb 2025].
177. ClinicalTrials.gov. Enfortumab Vedotin as monotherapy in patients with metastatic castration-resistant prostate cancer (ENCORE). Available from: https://clinicaltrials.gov/study/NCT04754191. [Last accessed on 19 Feb 2025].
178. Carebox. Study of AZD5305 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies. Available from: https://connect.careboxhealth.com/en-US/trial/listing/260668. [Last accessed on 18 Feb 2025].
179. National Cancer Institute. Study of Dato-Dxd as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumours (TROPION-PanTumor03). Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-07990. [Last accessed on 18 Feb 2025].
180. Larvol Clin Cancer Trial Results. Sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation AR-directed therapy. Available from: https://clin.larvol.com/trial-detail/NCT03725761. [Last accessed on 18 Feb 2025].
181. National Cancer Institute. Study of XB002 in Subjects With Solid Tumors (JEWEL-101). Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-11223. [Last accessed on 18 Feb 2025].
182. Chen QH, Munoz E, Ashong D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer. Cancers. 2024;16:663.
183. Rutherford KA, McManus KJ. PROTACs: current and future potential as a precision medicine strategy to combat cancer. Mol Cancer Ther. 2024;23:454-63.
184. Yedla P, Babalghith AO, Andra VV, Syed R. PROTACs in the management of prostate cancer. Molecules. 2023;28:3698.
185. Gao X, Burris Iii HA, Vuky J, et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022;40:17.
186. UroToday. ASCO 2024: ARV-766, a PROTAC androgen receptor degrader in mCRPC: initial results of a phase 1/2 study. Available from: https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer/152618-asco-2024-arv-766-a-protac-androgen-receptor-degrader-in-mcrpc-initial-results-of-a-phase-1-2-study.html. [Last accessed on 18 Feb 2025].
187. National Cancer Institute. Study to evaluate the safety and tolerability of CC-94676 in participants with metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-13275. [Last accessed on 18 Feb 2025].
188. CTV. A study to assess the safety, pharmacokinetics, and anti-tumor activity of oral HP518 in patients with metastatic castration-resistant prostate cancer. Available from: https://ctv.veeva.com/study/a-study-to-assess-the-safety-pharmacokinetics-and-anti-tumor-activity-of-oral-hp518-in-patients-wi. [Last accessed on 18 Feb 2025].
189. Ponnusamy S, Coss CC, Thiyagarajan T et al. Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Res. 2017;77:6282-98.
190. Wu M, Zhang R, Zhang Z et al. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. Elife. 2023;12:e70700.
191. Ponnusamy S, He Y, Hwang D-J et al. Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer. Clin Cancer Res. 2019;25:6764-80.
192. National Cancer Institute. A clinical study of ONCT-534 in subjects with metastatic castration-resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10317&r=1. [Last accessed on 18 Feb 2025].
193. Dale B, Cheng M, Park K-S, Kaniskan HÜ, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638-54.
194. He Q, Zhao X, Wu D, et al. Hydrophobic tag-based protein degradation: development, opportunity and challenge. Eur J Med Chem. 2023;260:115741.
195. Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24:880-90.
196. Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175-83.
197. ClinicalTrials.gov. [Ac-225]-PSMA-62 trial in oligometastatic hormone sensitive and metastatic castration resistant prostate cancer (ACCEL). Available from: https://clinicaltrials.gov/study/NCT06229366. [Last accessed on 19 Feb 2025].
198. ClinicalTrials.gov. 177Lu-PSMA-617 therapy and olaparib in patients with metastatic castration resistant prostate cancer (LuPARP). Available from: https://clinicaltrials.gov/study/NCT03874884. [Last accessed on 19 Feb 2025].
199. National Cancer Institute. Abemaciclib before 177Lu-PSMA-617 for the treatment of metastatic castrate resistant prostate cancer. Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-11123. [Last accessed on 18 Feb 2025].
200. Larvol Clin Cancer Trial Results. EVOLUTION: 177Lu-PSMA therapy versus 177Lu-PSMA in combination with ipilimumab and nivolumab for men with mCRPC. Available from: https://clin.larvol.com/trial-detail/NCT05150236. [Last accessed on 18 Feb 2025].
201. UCSF clinical trials. Pembrolizumab plus 177Lu-PSMA-617 in patients with castration resistant prostate cancer. Available from: https://clin.larvol.com/trial-detail/NCT05150236. [Last accessed on 18 Feb 2025].
202. Weill Cornell Medicine. Phase I/II trial of pembrolizumab and androgen-receptor pathway inhibitor with or without 225Ac-J591 for progressive metastatic castration resistant prostate cancer. Available from: https://jcto.weill.cornell.edu/open_clinical_trials/phase-iii-trial-of-pembrolizumab-and-androgen-receptor-pathway-inhibitor-with-or-without-225ac-j591-for-progressive-metastatic-castration-resistant-prostate-cancer. [Last accessed on 18 Feb 2025].
203. ClinicalTrials.gov. Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC. Available from: https://clinicaltrials.gov/study/NCT03093428. [Last accessed on 19 Feb 2025].
204. Larvol Clin Cancer Trial Results. Study of nivolumab in combination w radium-223 in men w metastatic castration resistant prostate cancer. Available from: https://clin.larvol.com/trial-detail/NCT04109729. [Last accessed on 18 Feb 2025].
205. Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28.
206. Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20:544-59.
207. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7:1893-902.
209. Noguchi M, Fujimoto K, Arai G, et al. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel. Oncol Rep. 2021;45:159-68.
210. Gulley JL, Borre M, Vogelzang NJ, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051-61.
211. Eriksson F, Tötterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine. 2013;31:3843-8.
212. McNeel DG, Eickhoff JC, Johnson LE, et al. Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer. J Clin Oncol. 2019;37:3507-17.
213. Kyriakopoulos CE, Eickhoff JC, Ferrari AC, et al. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res. 2020;26:5162-71.
214. Copur M. Messenger RNA vaccines: beckoning of a new era in cancer immunotherapy. Oncology. 2021;35:190-8.
215. Kübler H, Scheel B, Gnad-Vogt U et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3:26.
216. Stenzl A, Feyerabend S, Syndikus I, et al. 1149P - Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2017;28:v408-9.
217. McNeel DG, Eickhoff JC, Wargowski E, et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9:25586-96.
218. McNeel DG, Eickhoff JC, Wargowski E, et al. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2022;10:e004198.
219. Larvol Clin Cancer Trial Results. pTVG-HP and nivolumab in patients with non-metastatic PSA-recurrent prostate cancer. Available from: https://clin.larvol.com/trial-detail/NCT03600350. [Last accessed on 18 Feb 2025].
220. Center for Applied Genetics & Genomic Medicine. Neoantigen DNA vaccine in combination with nivolumab/ipilimumab and PROSTVAC in metastatic hormone-sensitive prostate cancer. Available from: https://precisionhealth.uahs.arizona.edu/clinical-trial/neoantigen-dna-vaccine-combination-nivolumabipilimumab-and-prostvac-metastatic. [Last accessed on 18 Feb 2025].
221. NIH Clinical Center. Docetaxel and prostvac for metastatic castration sensitive prostate cancer. Available from: https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=16-C-0048&&query=I. [Last accessed on 18 Feb 2025].
